OBJECTIVES: To determine whether computed tomography (CT)/magnetic resonance imaging (MRI) signs of vascular involvement are accurate after downstaging chemotherapy (DCTx) and to highlight factors associated with survival in patients who have undergone resection. DESIGN: Retrospective cohort study; prospective database. SETTING: University pancreatic disease center. PATIENTS: Patients with unresectable pancreaticobiliary cancer who underwent curative intent surgery after completing DCTx. INTERVENTIONS: Use of CT/MRI scan, pancreatic resection, and palliative bypass. MAIN OUTCOME MEASURES: Resectability after DCTx and disease-specific survival. RESULTS: We operated on 41 patients (1992-2009) with locally advanced periampullary malignant tumors after a median of 8.5 months of DCTx. Before DCTx, most patients (38 [93%]) were unresectable because of evidence of vascular contact on CT/MRI scan or operative exploration. Criteria for exploration after DCTx were CT/MRI evidence of tumor shrinkage and/or change in signs of vascular involvement, cancer antigen 19-9 decrease, and good functional status. None had progressive disease. At operation, we resected tumors in 34 of 41 patients (83%), and 6 had persistent vascular involvement. Surprisingly, CT/MRI scan was only 71% sensitive and 58% specific to detect vascular involvement after DCTx. "Involvement" on imaging was often from tumor fibrosis rather than viable cancer. Radiographic decrease in tumor size also did not predict resectability (P = .10). Patients with tumors that were resected had a median 87% decrease in cancer antigen 19-9 (P = .04) during DCTx. The median follow-up (all survivors) was 31 months, and disease-specific survival was 52 months for patients with resected tumors. CONCLUSIONS: In patients with initially unresectable periampullary malignant tumors, original CT/MRI signs of vascular involvement may persist after successful DCTx. Patients should be chosen for surgery on the basis of lack of disease progression, good functional status, and decrease in cancer antigen 19-9.
OBJECTIVES: To determine whether computed tomography (CT)/magnetic resonance imaging (MRI) signs of vascular involvement are accurate after downstaging chemotherapy (DCTx) and to highlight factors associated with survival in patients who have undergone resection. DESIGN: Retrospective cohort study; prospective database. SETTING: University pancreatic disease center. PATIENTS: Patients with unresectable pancreaticobiliary cancer who underwent curative intent surgery after completing DCTx. INTERVENTIONS: Use of CT/MRI scan, pancreatic resection, and palliative bypass. MAIN OUTCOME MEASURES: Resectability after DCTx and disease-specific survival. RESULTS: We operated on 41 patients (1992-2009) with locally advanced periampullary malignant tumors after a median of 8.5 months of DCTx. Before DCTx, most patients (38 [93%]) were unresectable because of evidence of vascular contact on CT/MRI scan or operative exploration. Criteria for exploration after DCTx were CT/MRI evidence of tumor shrinkage and/or change in signs of vascular involvement, cancer antigen 19-9 decrease, and good functional status. None had progressive disease. At operation, we resected tumors in 34 of 41 patients (83%), and 6 had persistent vascular involvement. Surprisingly, CT/MRI scan was only 71% sensitive and 58% specific to detect vascular involvement after DCTx. "Involvement" on imaging was often from tumor fibrosis rather than viable cancer. Radiographic decrease in tumor size also did not predict resectability (P = .10). Patients with tumors that were resected had a median 87% decrease in cancer antigen 19-9 (P = .04) during DCTx. The median follow-up (all survivors) was 31 months, and disease-specific survival was 52 months for patients with resected tumors. CONCLUSIONS: In patients with initially unresectable periampullary malignant tumors, original CT/MRI signs of vascular involvement may persist after successful DCTx. Patients should be chosen for surgery on the basis of lack of disease progression, good functional status, and decrease in cancer antigen 19-9.
Authors: Avani S Dholakia; Amy Hacker-Prietz; Aaron T Wild; Siva P Raman; Laura D Wood; Peng Huang; Daniel A Laheru; Lei Zheng; Ana De Jesus-Acosta; Dung T Le; Richard Schulick; Barish Edil; Susannah Ellsworth; Timothy M Pawlik; Christine A Iacobuzio-Donahue; Ralph H Hruban; John L Cameron; Elliot K Fishman; Christopher L Wolfgang; Joseph M Herman Journal: J Radiat Oncol Date: 2013-09-22
Authors: Colin M Court; Jacob S Ankeny; Shuang Hou; Hsian-Rong Tseng; James S Tomlinson Journal: Expert Rev Mol Diagn Date: 2015-09-21 Impact factor: 5.225
Authors: Colin M Court; Jacob S Ankeny; Shonan Sho; Paul Winograd; Shuang Hou; Min Song; Zev A Wainberg; Mark D Girgis; Thomas G Graeber; Vatche G Agopian; Hsian-Rong Tseng; James S Tomlinson Journal: Ann Surg Oncol Date: 2018-02-13 Impact factor: 5.344
Authors: Toshiro Masuda; Amanda M Dann; Irmina A Elliott; Hideo Baba; Stephen Kim; Alireza Sedarat; V Raman Muthusamy; Mark D Girgis; O Joe Hines; Howard A Reber; Timothy R Donahue Journal: J Gastrointest Surg Date: 2017-10-17 Impact factor: 3.452
Authors: L Loizou; N Albiin; B Leidner; E Axelsson; M A Fischer; A Grigoriadis; M Del Chiaro; R Segersvärd; C Verbeke; A Sundin; N Kartalis Journal: Eur Radiol Date: 2016-03-10 Impact factor: 5.315
Authors: Naveen M Kulkarni; Erik V Soloff; Parag P Tolat; Guillermo P Sangster; Jason B Fleming; Olga R Brook; Zhen Jane Wang; Elizabeth M Hecht; Marc Zins; Priya R Bhosale; Hina Arif-Tiwari; Lorenzo Mannelli; Avinash R Kambadakone; Eric P Tamm Journal: Abdom Radiol (NY) Date: 2020-03